Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Oct 16 - Oct 21
Cells 11 , 944 (2022)
The primary outcome was the prevalence of confirmed clinical neuropathy assessed by nerve conduction studies of the median, peroneal motor, and sural sensory nerves with a standard protocol
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance
Youre on a GLP-1 program and havent seen noticeable changes after 8 to 12 weeks at a therapeutic dose
Your experience depends on how well you follow your treatment plan, your diet and exercise habits, your metabolism, and other medications or conditions
US$ 23.02
US$ 21.15
US$ 25.62
US$ 22.26
